

TABLE OF CONTENTS

TITLE PAGE	i
APPROVAL PAGE	ii
AUTHENTICITY STATEMENT	iii
PREFACE.....	iv
TABLE OF CONTENTS.....	vi
LIST OF TABLES AND FIGURES.....	viii
LIST OF APPENDICES	ix
ABSTRACT.....	x
CHAPTER I INTRODUCTION.....	1
1.1. Background.....	1
1.2. Formulation of Problems	2
1.3. Aim of Research	3
1.4. Research Authenticity.....	4
1.5. Benefit of Research.....	5
CHAPTER II LITERATURE REVIEW.....	6
2.1. Theoretical Basis	6
2.1.1. Epstein- Barr Virus and Nasopharyngeal Carcinoma.....	6
2.1.2. Immune Response to EBV Infection	8
2.1.3. Environmental Factors and NPC Risk.....	8
2.1.4. Clinical Symptoms of Nasopharyngeal Carcinoma.....	9
2.2. Theoretical Framework.....	10
2.3. Conceptual Framework.....	11
2.4. Hypothesis	12
CHAPTER III METHOD OF RESEARCH	13
3.1 Research Type and Design	13
3.2. Research Subject and Population.....	13
3.3. Sample and Data Collection	13
3.4. Research Variable and Operational Definition.....	16
3.5. Reliability and Validity of Measurement	18
3.6. Data Analysis.....	19
CHAPTER IV RESULT AND DISCUSSION.....	20
4.1. Result	20
4.1.1. Subjects Characteristics	20
4.1.2. IgA- EBV Titer among Subjects.....	21
4.1.3. Dynamics of IgA-EBV Titer and Age of Subjects.	23

4.1.4. Dynamics of IgA-EBV Titer (Difference Value) Compared to IgG-EBV Immunoblot Pattern.....	24
4.1.5. Clinical Symptoms related to NPC in Subjects	27
4.1.6. Correlation between Dynamics of IgA-EBV, IgG- EBV Immunoblot Pattern, and Symptoms in Head and Neck in Subjects	27
4.2. Discussion.....	30
CHAPTER V CONCLUSION AND SUGGESTION	33
5.1. Conclusion	33
5.2. Suggestion	33
REFERENCES	34
APPENDICES	38

LIST OF TABLES AND FIGURES

Table 1: Review of Research related to the use of IgA EBV	4
Table 2. Subjects' characteristic	21
Table 3. Description of IgA-EBV (EBNA1+VCAp18) ELISA results.....	22
Table 4. IgA-EBV titer among subjects and subjects' age in comparison	24
Table 5. Comparison of Dynamics of IgA-EBV titer (difference value) and immunoblot test result.....	26
Table 6. Head and neck symptoms in subjects.....	27
Table 7. Correlation between Dynamics of IgA-EBV Titer, IgG-EBV immunoblot pattern, clinical symptoms related to NPC.....	29
Figure 1. Theoretical framework of the study.....	10
Figure 2. Conceptual framework of the study.....	11
Figure 3. Immunoblot strip	18
Figure 4. Dynamics of IgA-EBV titer among Subjects	23

LIST OF APPENDICES

Appendix 1. Ethical clearance of follow-up study.	38
Appendix 2. Survey form and informed consent form used in samples collection	39
Appendix 3. IgA (EBNA1+VCAP18) ELISA protocol procedure.	44
Appendix 4. Immunoblot detection using western blot method protocol procedure.	45